JP2010509366A5 - - Google Patents

Download PDF

Info

Publication number
JP2010509366A5
JP2010509366A5 JP2009536493A JP2009536493A JP2010509366A5 JP 2010509366 A5 JP2010509366 A5 JP 2010509366A5 JP 2009536493 A JP2009536493 A JP 2009536493A JP 2009536493 A JP2009536493 A JP 2009536493A JP 2010509366 A5 JP2010509366 A5 JP 2010509366A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
stereoisomer
solvate
acceptable salt
isoquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009536493A
Other languages
English (en)
Japanese (ja)
Other versions
JP5290185B2 (ja
JP2010509366A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/084176 external-priority patent/WO2008058261A1/en
Publication of JP2010509366A publication Critical patent/JP2010509366A/ja
Publication of JP2010509366A5 publication Critical patent/JP2010509366A5/ja
Application granted granted Critical
Publication of JP5290185B2 publication Critical patent/JP5290185B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009536493A 2006-11-08 2007-11-08 置換３−イソブチル−９，１０−ジメトキシ−１，３，４，６，７，１１ｂ−ヘキサヒドロ−２Ｈ−ピリド［２，１−ａ］イソキノリン−２−オール化合物およびそれに関連する方法 Active JP5290185B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86494406P 2006-11-08 2006-11-08
US60/864,944 2006-11-08
PCT/US2007/084176 WO2008058261A1 (en) 2006-11-08 2007-11-08 Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto

Publications (3)

Publication Number Publication Date
JP2010509366A JP2010509366A (ja) 2010-03-25
JP2010509366A5 true JP2010509366A5 (cg-RX-API-DMAC7.html) 2011-11-24
JP5290185B2 JP5290185B2 (ja) 2013-09-18

Family

ID=39110526

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009536493A Active JP5290185B2 (ja) 2006-11-08 2007-11-08 置換３−イソブチル−９，１０−ジメトキシ−１，３，４，６，７，１１ｂ−ヘキサヒドロ−２Ｈ−ピリド［２，１−ａ］イソキノリン−２−オール化合物およびそれに関連する方法

Country Status (16)

Country Link
US (2) US8039627B2 (cg-RX-API-DMAC7.html)
EP (1) EP2081929B1 (cg-RX-API-DMAC7.html)
JP (1) JP5290185B2 (cg-RX-API-DMAC7.html)
KR (1) KR101500766B1 (cg-RX-API-DMAC7.html)
CN (1) CN101553487B (cg-RX-API-DMAC7.html)
AU (1) AU2007317242B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0718247B1 (cg-RX-API-DMAC7.html)
CA (1) CA2668689C (cg-RX-API-DMAC7.html)
DK (1) DK2081929T3 (cg-RX-API-DMAC7.html)
EA (1) EA018378B1 (cg-RX-API-DMAC7.html)
ES (1) ES2402220T3 (cg-RX-API-DMAC7.html)
IL (1) IL198250A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009004910A (cg-RX-API-DMAC7.html)
PL (1) PL2081929T3 (cg-RX-API-DMAC7.html)
PT (1) PT2081929E (cg-RX-API-DMAC7.html)
WO (1) WO2008058261A1 (cg-RX-API-DMAC7.html)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039627B2 (en) 2006-11-08 2011-10-18 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
HUE038158T2 (hu) 2008-09-18 2018-09-28 Auspex Pharmaceuticals Inc Deuterizált benzokinolizin származékok vezikuláris monoamin transzporter-2 inhibitorként
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2012000308A1 (zh) * 2010-06-29 2012-01-05 中国药科大学 丁苯那嗪的拆分方法
US8351329B2 (en) * 2010-09-14 2013-01-08 Cisco Technology, Inc. Universal load-balancing tunnel encapsulation
CN102285984B (zh) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
WO2012081031A1 (en) 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
CA2883641C (en) 2012-09-18 2021-09-14 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
MX2015009719A (es) * 2013-01-31 2016-08-08 Auspex Pharmaceuticals Inc Inhibidores benzoquinolona de vmat2.
HK1221645A1 (zh) * 2013-09-27 2017-06-09 Auspex Pharmaceuticals, Inc. Vmat2的苯并喹啉抑制剂
CN105873589B (zh) * 2013-12-03 2019-11-01 奥斯拜客斯制药有限公司 制造苯并喹啉化合物的方法
KR20160111999A (ko) * 2014-01-27 2016-09-27 오스펙스 파마슈티칼스, 인코포레이티드 소포성 모노아민 수송체 2의 벤조퀴놀린 억제제
CN113413385A (zh) 2014-02-07 2021-09-21 纽罗克里生物科学有限公司 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
KR20160117596A (ko) 2014-02-07 2016-10-10 오스펙스 파마슈티칼스, 인코포레이티드 신규 제약 제제
CN106164066B (zh) 2014-02-13 2020-01-17 因赛特公司 作为lsd1抑制剂的环丙胺
DK3936130T3 (da) * 2014-05-06 2024-03-25 Neurocrine Biosciences Inc Doseringsskema for Valbenazin til behandling af hyperkinetiske bevægelsesforstyrrelser
AU2016215033B2 (en) * 2015-02-06 2020-06-25 Neurocrine Biosciences, Inc. (9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
JP6932641B2 (ja) 2015-03-06 2021-09-08 オースペックス ファーマシューティカルズ インコーポレイテッド 異常不随意運動障害の処置のための方法
CN107660205B (zh) 2015-04-03 2021-08-27 因赛特公司 作为lsd1抑制剂的杂环化合物
JP6919099B2 (ja) * 2015-06-23 2021-08-18 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 神経学的疾患または障害を処置するためのｖｍａｔ２阻害剤
EA035534B1 (ru) 2015-08-12 2020-06-30 Инсайт Корпорейшн Соли ингибитора lsd1
WO2017060870A1 (en) 2015-10-09 2017-04-13 Hermann Russ Combination of deuterated levodopa with carbidopa and opicapone for the treatment of parkinson`s disease
HRP20240304T1 (hr) * 2015-10-30 2024-05-10 Neurocrine Biosciences, Inc. Soli valbenazin dihidroklorida i njihovi polimorfi
LT3394057T (lt) 2015-12-23 2022-06-27 Neurocrine Biosciences, Inc. Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
WO2017182916A1 (en) * 2016-04-22 2017-10-26 Lupin Limited Novel process for preparation of tetrabenazine and deutetrabenazine
ES2811048T3 (es) 2016-06-29 2021-03-10 Crystal Pharmaceutical Suzhou Co Ltd Formas cristalinas de NBI-98854, método de preparación para las mismas y uso de las mismas
EP3523300A1 (en) * 2016-10-06 2019-08-14 Assia Chemical Industries Ltd. Solid state forms of valbenazine
EP4400171A3 (en) 2016-12-02 2024-09-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
US10703750B2 (en) 2017-01-10 2020-07-07 Sandoz Ag Crystalline valbenazine free base
KR20190108146A (ko) 2017-01-27 2019-09-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CA3054238A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
KR20230003308A (ko) 2017-03-15 2023-01-05 오스펙스 파마슈티칼스, 인코포레이티드 듀테트라베나진의 유사체, 이의 제조 및 용도
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JP7250692B2 (ja) * 2017-04-01 2023-04-03 アデプティオ ファーマシューティカルズ リミテッド 運動障害の治療における使用のためのジヒドロテトラベナジン
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JOP20190239A1 (ar) * 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
US20200179352A1 (en) 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
IL309802A (en) 2017-09-21 2024-02-01 Neurocrine Biosciences Inc High dose valbenazine formulation and related preparations, methods and kits
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CA3081709A1 (en) * 2017-11-08 2019-05-16 Yuhua Li Esters of dihydrotetrabenazine
WO2019104141A1 (en) 2017-11-22 2019-05-31 Teva Pharmaceuticals Usa, Inc. Solid state form of valbenazine
EP3733666B1 (en) 2017-12-26 2022-09-21 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of valbenazine di-p-toluenesulfonate, preparation method thereof and use thereof
CN110092785A (zh) * 2018-01-31 2019-08-06 广东东阳光药业有限公司 一种丁苯那嗪的动态拆分方法
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
WO2019241555A1 (en) * 2018-06-14 2019-12-19 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
JOP20200336A1 (ar) 2018-08-15 2020-12-22 Neurocrine Biosciences Inc طرق إعطاء مثبطات vmat2 معينة
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2020070236A1 (en) 2018-10-04 2020-04-09 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
CA3065236A1 (en) 2018-12-27 2020-06-27 Apotex Inc. Novel crystalline form of valbenazine dibesylate
WO2020213014A1 (en) 2019-04-19 2020-10-22 Mylan Laboratories Limited An improved process for the preparation of valbenazine and its salts
US10689380B1 (en) 2019-07-30 2020-06-23 Farmhispania S.A. Crystalline forms of valbenazine ditosylate
WO2021027792A1 (zh) * 2019-08-12 2021-02-18 山东绿叶制药有限公司 Vmat2抑制剂及其制备方法和应用
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CA3150961A1 (en) 2019-09-13 2021-03-18 John Tucker Processes for the synthesis of valbenazine
CN110698397A (zh) * 2019-10-28 2020-01-17 南京红杉生物科技有限公司 丁苯那嗪中间体及其合成方法、应用和合成用中间产物
JP2024511053A (ja) 2021-03-22 2024-03-12 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｖｍａｔ２阻害剤および使用方法
US20240239791A1 (en) 2021-04-26 2024-07-18 Neurocrine Biosciences, Inc. Processes for the synthesis of valbenazine
AU2022302155A1 (en) 2021-06-30 2024-02-08 Neurocrine Biosciences, Inc. Valbenazine for use in the treatment of dyskinesia due to cerebral palsy
JP2024524324A (ja) 2021-06-30 2024-07-05 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 統合失調症のアドオン処置において使用するためのバルベナジン
WO2023172849A1 (en) 2022-03-07 2023-09-14 Neurocrine Biosciences, Inc. Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
CN119907800A (zh) 2022-09-21 2025-04-29 纽罗克里生物科学有限公司 六氢-2H-吡啶并[2,1-a]异喹啉VMAT2抑制剂及其使用方法
WO2025038938A1 (en) 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Valbenazine for use in the treatment of huntington's chorea
WO2025038959A1 (en) 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
WO2025096823A1 (en) 2023-11-01 2025-05-08 Neurocrine Biosciences, Inc. Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
WO2025188830A1 (en) 2024-03-06 2025-09-12 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
WO2025199234A1 (en) 2024-03-20 2025-09-25 Neurocrine Biosciences, Inc. Vmat2 inhibitors and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3209005A (en) * 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US2843591A (en) * 1958-07-15 Method for preparing same
US2852518A (en) * 1957-05-23 1958-09-16 Parke Davis & Co Di-substituted quinoline compounds
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
US7045543B2 (en) * 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
WO2007005283A2 (en) 2005-06-29 2007-01-11 Trustees Of Columbia University In The City Of New York Use of dtbz for imaging endocrine pancreas and beta cell mass in type 1 diabetes
GB0514501D0 (en) 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0516168D0 (en) 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
EP1855677B1 (en) 2005-08-06 2008-12-03 Cambridge Laboratories (Ireland) Limited 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
US8039627B2 (en) 2006-11-08 2011-10-18 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto

Similar Documents

Publication Publication Date Title
JP2010509366A5 (cg-RX-API-DMAC7.html)
JP2009504763A5 (cg-RX-API-DMAC7.html)
MY202837A (en) Lipids for lipid nanoparticle delivery of active agents
EP4501322A3 (en) Lipids for use in lipid nanoparticle formulations
EP4566670A3 (en) Modulators of pharmacokinetic properties of therapeutics
JP2010511626A5 (cg-RX-API-DMAC7.html)
JP2018504437A5 (cg-RX-API-DMAC7.html)
JP2015518004A5 (cg-RX-API-DMAC7.html)
WO2005063745A8 (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
JP2009504764A5 (cg-RX-API-DMAC7.html)
JP2011517683A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
EP4473980A3 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
RU2017112048A (ru) Синергистические комбинации ауристана
JP2013503846A5 (cg-RX-API-DMAC7.html)
JP2006182786A5 (cg-RX-API-DMAC7.html)
JP2009502743A5 (cg-RX-API-DMAC7.html)
JP2009535358A5 (cg-RX-API-DMAC7.html)
JP2013510885A5 (cg-RX-API-DMAC7.html)
RU2015107803A (ru) Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания
JP2010077141A5 (cg-RX-API-DMAC7.html)
JP2012503621A5 (cg-RX-API-DMAC7.html)
JP2014518882A5 (cg-RX-API-DMAC7.html)
JP2019532928A5 (cg-RX-API-DMAC7.html)
RU2008146816A (ru) Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол